FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2024/03/063719 [Registered on: 06/03/2024] Trial Registered Prospectively
Last Modified On: 06/03/2024
Post Graduate Thesis  No 
Type of Trial  Observational 
Type of Study   Follow Up Study 
Study Design  Other 
Public Title of Study   Data collection for outcomes after any surgery in patients wih liver cirrhosis 
Scientific Title of Study   Multicenter registry for surgical outcomes in liver cirrhosis 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Abhinav Jain 
Designation  consultant 
Affiliation  Gastro1 Hospital 
Address  411, Dept of gastroenterology, Noble trade center, Oppo BD rao hall, Bhuyangdev, Ahmedabad

Ahmadabad
GUJARAT
380052
India 
Phone  7666373288  
Fax    
Email  dr.a.j.12320@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Abhinav Jain 
Designation  consultant 
Affiliation  Gastro1 Hospital 
Address  411, Dept of Gastroenterology, Noble trade center, Oppo BD rao hall, Bhuyangdev, Ahmedabad


GUJARAT
380052
India 
Phone  7666373288  
Fax    
Email  dr.a.j.12320@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Abhinav Jain 
Designation  consultant 
Affiliation  Gastro1 Hospital 
Address  411, Dept of Gastroenterology, Noble trade center, Oppo BD rao hall, Bhuyangdev, Ahmedabad


GUJARAT
380052
India 
Phone  7666373288  
Fax    
Email  dr.a.j.12320@gmail.com  
 
Source of Monetary or Material Support  
Gastro1 Hospital 
 
Primary Sponsor  
Name  Abhinav Jain 
Address  Gastro1 Hospital, 411, Dept of Gastroenterology, Noble trade center, Oppo BD rao hall, Bhuyangdev, Ahmedabad 
Type of Sponsor  Other [self] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Abhinav Jain  Gastro1 hospital  411, Dept of Gastroenterology, Noble trade center, Oppo BD rao hall, Bhuyangdev, Ahmedabad
Ahmadabad
GUJARAT 
7666373288

dr.a.j.12320@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Ethics Committee of Care Institute of Medical Science  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: K746||Other and unspecified cirrhosis ofliver,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Nil  Nil 
Comparator Agent  Nil  Nil 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  80.00 Year(s)
Gender  Both 
Details  Liver cirrhosis with any surgery done 
 
ExclusionCriteria 
Details  Not giving consent 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Other 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
Decompensation, infections and mortality  1 and 6 months 
 
Secondary Outcome  
Outcome  TimePoints 
Decompensation, infections & mortality  3 months 
 
Target Sample Size   Total Sample Size="1000"
Sample Size from India="1000" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   18/03/2024 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="5"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Yet Recruiting 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Title:

Prospective multicentre surgical outcome registry for patients with cirrhosis of liver

 

Introduction:

The prevalence of cirrhosis of the liver is increasing globally and also in India. [1,2]. This translates to a growing number of patients with cirrhosis of liver undergoing surgeries. There is an increased risk of post-operative mortality as well as decompensation for patients with liver cirrhosis undergoing surgery. [3,4].

Risk stratification and prediction of complications and/or mortality is necessary for informed decision making for patient and surgeon, both. Numerous risk prediction models are currently available, and the most used are the Mayo score[3] and the VOCAL- Penn scoring system[4].

While Mayo score only predicted mortality, VOCAL-Penn score also predicted decompensation andpost-operative infection in addition to mortality. The VOCAL-Penn database is based on retrospective data of patients with cirrhosis who underwent diverse surgeries in the Veterans Health Administration, based in US. [4] This includes only 1.1% of Asians and a majority of patients had hepatitis C, along with alcohol as etiology of liver cirrhosis. The Indian population of cirrhosis would differ as compared to this cohort with respects to composition, etiology and possibly a worse nutrition and albumin level.

Thus, it is felt necessary to have a prospective registry of surgical outcomes in patients with cirrhosis of liver in India.

Methods:

1.       Study design: Prospective, multicenter, observational study

 

2.       Patient selection

All patients with cirrhosis of liver who undergo any surgical intervention will be eligible for the study. Patients will also receive a written explanation of the study and must freely give their informed consent in writing.Patients must fulfil the inclusion and exclusion criteria.

Inclusion criteria

·         Aged 18 years or older 

·         Confirmed cirrhosis of liver as below

o   A combination of clinical, imaging and biochemical findings

o   Liver biopsy confirming bridging fibrosis or F4 on Metavir staging

o   Visualisation of nodular cirrhosis on laparoscopy or laparotomy during surgery

o   Ultrasound or CT demonstrating a shrunken and nodular liver

o   Liver elastography showing >15 kPa, in absence of cardiac failure, liver tumors, biliary obstruction and ascites.

·         Informed consent

Exclusion criteria

·         Co-existing hepatocellular carcinoma

·         Liver transplant surgery

·         Consent refused

 

3.       Variable collection

Baseline:

·         Demographic data such as age, gender, state of residence

·         Comorbidities: hypertension, diabetes, obesity [BMI ≥ 30], coronary artery disease, congestive heart failure, chronic kidney disease, chronic obstructive pulmonary disease, ischaemic stroke

·         Etiology of liver cirrhosis. This will be classified as alcohol related, NASH, hepatitis B, hepatitis C, Autoimmune liver disease (including autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cirrhosis and/or any combination), Wilson’s disease and others. For rare liver diseases, the name will be noted down. For those with multiple etiologies, all the etiologies will be recorded.

·         Biochemical tests including complete blood count, S. creatinine, sodium, liver function tests such as total bilirubin(or direct bilirubin wherever available), AST (aspartate aminotransferase), ALT (Alanine aminotransferase), alkaline phosphatase, albumin and prothrombin time with test value, control value and international normalized ratio (INR). The relevant Child-Turcotte-Pugh (CTP)and MELD-Na scores will be calculated based on these values. [Appendix 1]. These values would be within 72 hours of the surgery to be considered valid. Additional values like pH, lactate, CRP, procalcitonin will be recorded whenever available.

·         Compensated or decompensated cirrhosis. If decompensation exists, type of decompensation and grade will be noted. [Appendix 2]

·         Acute on chronic liver failure (ACLF) present or not [Appendix 3] [5]

Surgical  details:

·         Details of surgery [appendix 4 for details]

o   Date of surgery.

o   Emergency or elective #

o   Name of surgery performed *

o   Duration of the surgery

o   Approximate blood loss intra-operatively @

o   Whether surgery is done for an infectious complication

·         Details of anaesthesia

o   ASA (American Society of Anaesthesiologists) classification [appendix 5] [6]

o   Type of anaesthesia given: Local, regional, spinal, general

o   Major events occurring intra-operatively like hemodynamic instability

 

Outcome

The outcome will be noted at Day 7, 1 month (Day 30), 3 months (Day 60) and 6 months (Day 180).

The timing will be considered from the date of surgery, which will be Day 0.

There will be an allowance of a window period of +/- 7 days for each of the assessments, except for assessment at Day 7, where the window period will be of +/- 3 days.

·         Mortality will be recorded. The number of days for the death from the day of surgery will be calculated and recorded.

·         Occurrence of any new liver related decompensation will be recorded. This will be classified into acute decompensation or ACLF and graded accordingly [Appendix 2 & 3]. Non variceal bleeding will not be considered as a decompensation.

·         Worsening of pre-existing decompensation will be recorded. Grading will be noted as per appendix 2.

·         Occurrence of infections will be noted along with site and severity [Appendix 6]. Only new onset infections will be considered. Pre-existing infections before surgery will not be considered.

·         Biochemical tests including complete blood count, S. creatinine, sodium, liver function tests such as total bilirubin(or direct bilirubin wherever available), AST (aspartate aminotransferase), ALT (Alanine aminotransferase), alkaline phosphatase, albumin and prothrombin time with test value, control value and international normalized ratio (INR) will be recorded whenever available. The relevant Child-Turcotte-Pugh (CTP)and MELD-Na scores will be calculated based on these values. [Appendix 1].  Additional values like pH, lactate, CRP, procalcitonin will be recorded whenever available.

 

Collection of data

The data will be collected via a website. The investigators will be given a username and password for identification and authentication.

The Clinical record form (CRF) will be electronic and will be saved on server online. They will be editable till the 6 month follow up is completed.

 

References:

1.       10.1016/S2468-1253(19)30349-8 (global trend)

2.       10.1002/cld.1177 (India)

3.       10.1053/j.gastro.2007.01.040 (Mayo score)

4.       10.1016/j.cgh.2021.06.050 (Vocal Penn)

5.       10.1007/s12072-019-09946-3 (APASL ACLF)

6.       https://www.asahq.org/standards-and-guidelines/asa-physical-status-classification-system [ASA classification]

7.       10.1007/s40265-018-1018-z (West Haven)

8.       10.1016/j.jhep.2010.05.004 (EASL ascites, HRS)

9.       10.1002/hep.22605 (AASLD AKI)

 


 

Appendix

1.      CHILD-TURCOTTE-PUGH (CTP) AND MELD-NA SCORES

 

Child-Turcotte-Pugh (CTP)

CTP class A: score 5-6 points

CTP class B: Score 7-9 points

CTP class C: Score 10-15 points

MELD score:

MELD Score = (0.957 * ln(Serum Cr) + 0.378 * ln(Serum Bilirubin) + 1.120 * ln(INR) + 0.643 ) * 10 (if hemodialysis, value for Creatinine is automatically set to 4.0)

MELD-Na = MELD Score - Na - 0.025 x MELD x (140-Na) + 140


 

 

2.      DECOMPENSATION NOTATION AND GRADING

 

List of decompensations:

·         Hepatic encephalopathy

·         Acute Kidney Injury

·         Hepato-renal syndrome (HRS)

·         Ascites

·         Variceal bleeding

·         Jaundice

·         Coagulopathy

·         New onset portal vein thrombosis

Grading of Hepatic Encephalopathy [7]

Minimal

Detected on psychometric testing without any obvious clinical mental changes

Grade 1

Trivial lack of awareness

Euphoria or anxiety

Short attention span

Impaired performance in doing mathematical problems (specially subtraction)

Grade 2

Lethargy or apathy

Disorientation to time

Obvious personality change

Inappropriate behavious

Grade 3

Somnolence to semi-stupor, but responsive to verbal stimuli

Confusion

Gross disorientation

Bizarre behaviour

Grade 4

Comatose

 

Grading of ascites [8]

Grade 1

Mild ascites only detectable by ultrasound

Grade 2

Moderate ascites evident by moderate symmetrical distension of abdomen

Grade 3

Large or gross ascites with marked abdominal distension

 

Acute Kidney Injury grading [9]

Stage

criteria

Urine criteria

1

Increase in serum creatinine of more than or equal to 0.3 mg/dL or increase to more than or equal to 150% to 200% (1.5-fold to 2-fold) from baseline

Less than 0.5 mL/kg per hour for more than 6 hours

2

Increase in serum creatinine to more than 200% to 300% (>2-fold to 3-fold) from baseline

Less than 0.5 mL/kg per hour for more than 12 hours

3

Increase in serum creatinine to more than 300% (>3-fold) from baseline (or serum creatinine of more than or equal to 4.0 mg/dL with an acute increase of at least 0.5 mg/dL)

Less than 0.3 mL/kg per hour for 24 hours or anuria for 12 hours

 

Diagnostic criteria of Hepato-renal syndrome (HRS) [9]

·         Cirrhosis with ascites

 

·         Serum creatinine >1.5 mg/dL

 

·         HRS-1 doubling of the initial serum creatinine concentrations to a level greater than 2.5 mg/dL (>226 μmol/L) in less than 2 weeks

 

·         No improvement in serum creatinine (decrease to 1.5 mg/dL or less) after at least 2 days of diuretic withdrawal and expansion of plasma volume with albumin (1 g/kg body weight/day up to a maximum of 100 g/day)

 

·         Absence of shock

 

·         No current or recent treatment with nephrotoxic drugs or vasodilators

 

·         Absence of parenchymal kidney disease as indicated by proteinuria >500 mg/day, microhematuria (>50 red blood cells per high-power field), or abnormal renal ultrasonography

 

Grading of Jaundice:

 

Any increase or decrease in serum Bilirubin will be noted as a percentage (%) of the previous value.

 

Grading of coagulopathy:

 

Any increase or decrease in prothrombin time will be noted as a percentage (%) of the previous value.

 

 

3.      ACUTE ON CHRONIC LIVER FAILURE (ACLF)

 

ACLF is defined as following as per APASL consensus:

ACLF is an acute hepatic insult manifesting as jaundice (serum bilirubin≥5 mg/dL) and coagulopathy (INR≥1.5 or prothrombin activity < 40%) complicated within 4 weeks by clinical ascites and/or encephalopathy in a patient with previously diagnosed or undiagnosed chronic liver disease/cirrhosis, and is associated with a high 28-day mortality.


 

 

 

4.      SURGICAL DETAILS

 

·         Emergency surgeries will be defined as those requiring surgical intervention within 24 hours of admission to the hospital. The decision will be taken by attending clinician based on indication on indication of surgery and patient factors.

·         Name of surgery performed:  A list of standardised nomenclature will be generated after first hundred registrations. The surgeries with minor technical variations will be considered into a single category. If more than one surgery is performed in a single session, the surgery with higher complexity will be considered. The complexity in such cases will be subjectively based on expected mortality rate, amount of trauma, extent of dissection, potential functional or cosmetic loss, usual duration of operation, space requirements, equipment required, anaesthesia use, number of assistants required, and special training required. The decision will be taken by the attending clinician. If more than one complex surgery is performed, both the surgical procedures will be noted

·         The estimation of blood loss will be provided by the attending clinician. Method used to estimate the  blood loss will be recorded. E.g. visual, formula based, gravimetric etc


 

 

5.      ASA PHYSICAL STATUS CLASSIFICATION SYSTEM

ASA 1: A normal healthy patient

ASA 2: A patient with mild systemic disease

ASA 3: A patient with severe systemic disease

ASA 4: A patient with severe systemic disease that is a constant threat to life

ASA 5: A moribund patient who is not expected to survive without the operation

ASA 6: A declared brain-dead patient whose organs are being removed for donor purposes

 

Patients with cirrhosis of liver will have at least ASA class 3

Those with current decompensation will have ASA class 4

Only those who are not known to be cirrhosis and are detected to have cirrhosis intra-operatively will be ASA class 2.

They shall be re-classified as ASA grade 3. [3,4]

 

6.       INFECTIONS

List of infections to be noted:

·         Urinary tract infections

·         Pneumonia

·         Wound superinfection

·         Skin/soft tissue infection

·         Spontaneous Bacterial peritonitis

·         Sepsis

·         Other

 

 

 

 

 
Close